Management of Chronic Prurigo and Prurigo Nodularis with Systemic Janus Kinase Inhibitors: An Evidence-Based Review

Abstract

Keywords

chronic prurigo prurigo nodularis Janus kinase inhibitor systematic review evidence-based

Get full access to this article

View all access options for this article.

References

Ständer

Pereira

Berger

, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi:10.1097/itx.0000000000000042

Parthasarathy

Cravero

Deng

, et al. Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis. Front Med (Lausanne). 2022;9:1011142. doi:10.3389/fmed.2022.1011142

Tokura

Yagi

Hanaoka

, et al. Subacute and chronic prurigo effectively treated with recombination interferon-gamma: implications for participation of Th2 cells in the pathogenesis of prurigo. Acta Derm Venereol. 1997;77(3):231-234. doi:10.2340/0001555577231234

Fukushi

Yamasaki

Aiba

. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990-996. doi:10.1111/j.1365-2133.2011.10498.x

Kwatra

Bordeaux

Parthasarathy

, et al. Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial. JAMA Dermatol. 2024;160(7):717-724. doi:10.1001/jamadermatol.2024.1464

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

0.04 MB

0.02 MB

2.17 MB